EUCTR2020-002872-11-NL进行中（未招募）1 期
A Phase 2a, open-label, multicenter study to evaluate the safety and tolerability of repeated administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors; MSC-NTF cells) in participants with prodromal to mild Alzheimer’s Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Males and females, ages 50 to 75 years old, inclusive, at the Screening Visit (Visit 1).
- •2.Clinical diagnosis of prodromal to mild AD at least 6 months prior to enrollment, based on the International Working Group (IWG-2) diagnostic criteria or the National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria.
- •3.Mini Mental State Examination (MMSE) of 20-30, inclusive, and Clinical dementia rating-global score (CDR-GS) of 0.5 or 1.0
- •4.Demonstrated abnormal memory function
- •5.CSF profile consistent with AD: Amyloid Beta 42 (Aß42) concentration of <1000 pg/ml AND P-tau >19 pg/ml or ratio of p-tau/Abeta > 0.024 (Elecsys assay)
- •6.If currently treated with Cholinesterase Inhibitors (AChEI) (donepezil, galantamine, or rivastigmine) or Memantine the dose should be stable for at least 12 weeks prior to Screening (Visit 1).
- •7.Must have a caregiver that is willing to participate in the study and is able to provide accurate information on the participant's cognitive and functional ability.
- •8.Must consent to apolipoprotein E (ApoE) genotyping or willing to provide previous test results.
- •9.If sexually active and of childbearing potential, both females and males must agree to use an effective birth control method during the study and for at least 3 months following the last transplantation, such as: abstinence, intrauterine device (IUD), oral contraception, barrier and spermicide or hormonal implant.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1.Prior stem cell therapy of any kind.
- •2.Active participation in any other interventional study or use of unapproved AD investigational therapy within 60 days prior to the Screening Visit (Visit 1), unless proven to have been on placebo.
- •3.Inability to lie flat for the duration of intrathecal cell administration and/or bone marrow aspiration, or inability to tolerate study procedures for any other reason.
- •4.History of clinically significant autoimmune disease (excluding thyroid disease) that may confound study results, myelodysplastic or myeloproliferative disorder, leukemia or lymphoma, whole body irradiation, hip fracture, or severe scoliosis.
- •5.Any poorly controlled clinically significant medical condition other than Alzheimer’s disease (e.g., within six months of Screening Visit (Visit 1), such as myocardial infarction, angina pectoris, congestive heart failure, or hypertension (repeated blood pressure >180 mmHg systolic or 100 mmHg diastolic) as well as clinically significant coagulopathy, treatment with anticoagulants that, in the opinion of the investigator, would compromise the safety of participants.
- •6.Any history of malignancy (e.g., myeloproliferative disorder, leukemia or lymphoma) within the previous 5 years, except for non-melanoma localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of Screening Visit (Visit 1)).
- •7.Any history of acquired or inherited immune deficiency syndrome.
- •8.Platelet count, INR, PT or PTT not within the normal range (local protocol) or other risk for increased or uncontrolled bleeding (safety for lumbar puncture and bone marrow).
- •9.Presence of contraindication to lumbar puncture as judged by local PI, e.g. need for anticoagulant or antiplatelet medications other than aspirin at a dose of = 100 mg/day or clopidogrel.
- •10.MRI evidence of a) more than three lacunar infarcts, b) territorial infarct or macroscopic hemorrhage, or c) deep white matter lesions (corresponding to a Fazekas score of 3).
- •11.Pregnant women or women currently breastfeeding.
- •12.Positive test result for Hepatitis B virus (HBV; surface antigen (HBsAg) and antibodies to core antigen (IgG and IgM anti-HBc)), Hepatitis C virus (HCV), Human Immune deficiency Virus (HIV) 1 and 2.
- •13.Any medical or neurological/neurodegenerative condition other than AD (e.g.,vascular dementia, dementia with Lewy bodies, and Parkinson’s disease) that, in the opinion of the Investigator, might be a contributing cause to the participant's cognitive impairment or could lead to discontinuation, lack of compliance, interference with study assessments, or safety concerns (includes, low vitamin B12 level, low Hb level (<100); hypothyroid disease).
- •14.History within the past 6 months or evidence of clinically significant psychiatric illness (e.g., major depression, suicidality, schizophrenia, or bipolar affective disorder).
- •15.Any condition, which in the opinion of the investigator or the Sponsor makes the patient unsuitable for inclusion.
研究者
相似试验
进行中（未招募）
不适用
A phase II, open-label, multicentre study to evaluate the pharmacodynamic profile, the efficacy and the safety of a 6-month sustained-release formulation of triptorelin in patients with prostate cancer - Not applicableEUCTR2006-007055-41-LTBeaufour Ipsen Pharma - 24, rue Erlanger 75016 Paris FRANCE12
进行中（未招募）
1 期
A phase II, open-label, multicentre study to evaluate the safety and immunogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine as a booster dose in children aged 12 to 18 months, previously primed with the same vaccine in the primary vaccination study DTPa-HBV-IPV=Hib-MenC-TT-002 (112157). - DTPA-HBV-IPV=HIB-MENC-TT-004 BST: 002Booster immunization of healthy children in the second year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Haemophilus influenzae type b (Hib) and serogroup C meningococcal (Men C) diseases.EUCTR2010-019253-18-PLGlaxoSmithKline Biologicals
进行中（未招募）
1 期
A study to assess the safety and clinical activity of durvalumab as combination therapy on previously untreated people with high risk diffuse large b-cell lymphomaEUCTR2015-005173-20-ATCelgene International II Sàrl45
进行中（未招募）
1 期
A study to assess the safety and clinical activity of durvalumab as combination therapy on previously untreated people with high risk diffuse large b-cell lymphomaPreviously untreated, high-risk diffuse-large B-cell lymphoma (DLBCL)MedDRA version: 20.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005173-20-EECelgene International II Sàrl120
进行中（未招募）
1 期
A study to assess the safety and clinical activity of durvalumab as combination therapy on previously untreated people with high risk diffuse large b-cell lymphomaPreviously untreated, high-risk diffuse-large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005173-20-DKCelgene International II Sàrl45